Risk-adapted Treatment Strategy For COVID-19 Patients
Fecha
2020-03-23Autor
Zheng, Changcheng
Wang, Jinquan
Guo, Hui
Lu, Zhaohui
Ma, Yan
Zhu, Yuyou
Xia, Daqing
Wang, Yinzhong
He, Hongliang
Zhou, Jian
Wang, Yong
Fei, Mingming
Yin, Yihong
Zheng, Mao
Xu, Yehong
Anhui Medical team members of National aid to prevent and treat novel coronavirus pneumonia in Wuhan
Documentos PDF
Resumen en idioma extranjero
Background
There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19.
Methods
We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity.
Results
Twelve patients were in mild group and 22 were in moderate group (non-severe group, n = 34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p = 0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p = 0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p = 0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis.
Conclusions
Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production.
Palabras clave
novel coronavirus pneumonia; risk-adapted treatment strategy; antiviral treatment; low-dose corticosteroidColecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.